Bluejay Diagnostics announces $4.5M private placement priced at-the-market

Bluejay Diagnostics (BJDX) announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2.25M shares of common stock and Series F warrants to purchase up to 4.5M shares of common stock at a purchase price of $2.00 per share of common stock and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The Series F warrants will have an exercise price of $1.75 per share and will be exercisable immediately upon issuance. The Series F warrants will expire 5.5 years from the date of issuance. The private placement is expected to close on or about October 10, subject to the satisfaction of customary closing conditions. Rodman and Renshaw is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be $4.5M, prior to deducting placement agent’s fees and other offering expenses payable by the company.